Basilea Pharmaceutica AG is a Swiss pharmaceutical company headquartered in Basel, Switzerland, dedicated to developing and commercializing innovative anti-infective products for patients with severe and life-threatening bacterial and fungal infections [@basilea]. Founded in 2001 and celebrating its 25th anniversary in 2026, Basilea operates at the forefront of anti-infective drug development, focusing on the growing challenge of antimicrobial resistance (AMR) in hospital settings. The company is listed on the SIX Swiss Exchange (SIX: BSLN) and maintains a market capitalization of approximately CHF 600 million [@basilea].
Strategic Focus
Basilea's strategic focus centers on addressing the global antimicrobial resistance crisis through: 1. Novel antifungals: Developing next-generation antifungal agents for invasive infections 2. Novel antibiotics: Creating new antibiotic classes to combat resistant bacteria 3. Hospital-focused products: Targeting infections in immunocompromised and hospitalized patients 4. Global commercialization: Building partnerships for worldwide market access
The company's research and development activities are concentrated in the Basel region, leveraging the world-class life sciences ecosystem that includes major pharmaceutical companies, academic institutions, and research hospitals [@basilea-rd].
Growth and Product Development (2010-2020)
The 2010s marked Basilea's transition from a research-focused biotech to a commercial-stage pharmaceutical company:
...
Basilea Pharmaceutica AG is a Swiss pharmaceutical company headquartered in Basel, Switzerland, dedicated to developing and commercializing innovative anti-infective products for patients with severe and life-threatening bacterial and fungal infections [@basilea]. Founded in 2001 and celebrating its 25th anniversary in 2026, Basilea operates at the forefront of anti-infective drug development, focusing on the growing challenge of antimicrobial resistance (AMR) in hospital settings. The company is listed on the SIX Swiss Exchange (SIX: BSLN) and maintains a market capitalization of approximately CHF 600 million [@basilea].
Strategic Focus
Basilea's strategic focus centers on addressing the global antimicrobial resistance crisis through: 1. Novel antifungals: Developing next-generation antifungal agents for invasive infections 2. Novel antibiotics: Creating new antibiotic classes to combat resistant bacteria 3. Hospital-focused products: Targeting infections in immunocompromised and hospitalized patients 4. Global commercialization: Building partnerships for worldwide market access
The company's research and development activities are concentrated in the Basel region, leveraging the world-class life sciences ecosystem that includes major pharmaceutical companies, academic institutions, and research hospitals [@basilea-rd].
Growth and Product Development (2010-2020)
The 2010s marked Basilea's transition from a research-focused biotech to a commercial-stage pharmaceutical company:
2015: FDA approval of Cresemba (isavuconazole) [@cresemba]
2016: EMA approval of Cresemba [@cresemba]
Commercial partnerships: Agreements with Pfizer, Astellas, and other partners for global commercialization [@cresemba]
Pipeline expansion: Initiation of multiple Phase 2 and Phase 3 programs
Recent Developments (2020-Present)
The recent period has seen continued pipeline advancement:
2024: Continued growth of Cresemba sales
2025: Initiation of first-in-human studies for BAL2420 [@basilea-pipeline]